“Blossom is democratising access to psychedelic research by presenting papers from a broad range of disciplines in an accessible weekly write-up.”
Whether you're scouting the next breakthrough compound, conducting due diligence, or designing a trial, fragmented data creates blind spots. Efficient execution requires seeing the full picture—instantly.
Manual tracking via spreadsheets, relying on stale datasets, and missing critical signals buried in paywalled journals.
A unified intelligence layer. Real-time trial tracking, comprehensive compound landscaping, and expert-vetted insights to de-risk your strategy.
Freshly decoded research, clinical trial updates, and country snapshots pulled directly from the lab to your screen.
Topic overview
Depression is the most studied indication in psychedelic science, with multiple compounds now in Phase III trials. While the first FDA approvals are projected for 2027, patients currently access care through clinical trials, specialized psilocybin programs, or widespread ketamine and Spravato treatments.
Latest paper
This repeated-measures dose-dependent study (n=19) investigates DMT's subjective and neural dynamics under naturalistic conditions. Participants received 20mg or 40mg doses of freebase DMT in a blinded, counterbalanced design, with EEG data and time-resolved subjective measures collected. The 40mg dose produced more intense visual hallucinations and emotional responses. Neural analyses revealed alpha power and permutation entropy were most associated with subjective experiences, whereas lempel-ziv complexity was less predictive, challenging prior assumptions about its role in psychedelic states.
Latest trial
Phase IIb randomised, double-blind trial (n=96) comparing two doses of psilocybin (25 mg vs 5 mg) plus psychological support; two doses given one month apart with outcomes over 33 weeks in adults with severe GAD.
Country snapshot
A global research hub hosting the ICPR conference and pioneering work at top universities and CROs. Despite strict clinical laws, the Netherlands maintains a unique legal status for psilocybin truffles, supporting a world-leading ecosystem of professional coaching and retreats.
Timeless guides, safety protocols, and methodology explainers to help you master the core concepts of psychedelic science.
Guide
Screening, risk mitigation, and red flags across compounds.
Playbook
Session prep, dosing day flow, and integration essentials.
Snapshot
How access is evolving—designations, pilots, and timelines.
How-to
Endpoints, scales, and evaluation frameworks to compare studies.
Explore the full depth of our intelligence layer. Thousands of datapoints across compounds, people, and markets.
Peer-reviewed literature and summaries.
Interventional and observational studies.
Evidence by molecule and safety signals.
Clinical signals across disorders.
Themes that connect research and practice.
Policy and access snapshots by market.
Organizations shaping the field.
Researchers, clinicians, and advocates.
Training and education pathways.
Conferences and gatherings to watch.
Policy shifts, funding, and headlines.
Pricing that scales with you
Choose the plan that fits your research needs. From individual access to enterprise-grade data solutions.
For solo therapists, individual PhD students, and researchers.
USD
per year
For university labs, Ketamine clinic networks, and boutique funds.
USD
per year
For large organizations, pharma companies, and VC funds.
USD
per year